Structure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Key Points

• Structure Therapeutics reported a quarterly loss of ($0.36) EPS, falling short of analysts' expectations of ($0.28) by $0.08.
• After the earnings announcement, shares of Structure Therapeutics traded at $16.26, indicating a decline from a 50-day moving average of $19.89.
• Despite recent earnings miss, several analysts maintain a "buy" rating for the stock, with target prices ranging from $60.00 to $90.00.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08), Zacks reports.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR traded up $0.41 on Wednesday, hitting $19.15. The company's stock had a trading volume of 111,916 shares, compared to its average volume of 873,516. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $45.37. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -18.24 and a beta of -1.89. The stock's 50-day moving average is $19.63 and its two-hundred day moving average is $21.67.

Institutional Trading of Structure Therapeutics

A hedge fund recently raised its stake in Structure Therapeutics stock. Geode Capital Management LLC increased its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 18.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,181 shares of the company's stock after buying an additional 8,444 shares during the quarter. Geode Capital Management LLC owned about 0.09% of Structure Therapeutics worth $1,124,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 91.78% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GPCR shares. JMP Securities lowered their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Citigroup started coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective for the company. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, June 23rd. HC Wainwright lowered their price objective on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, Guggenheim lowered their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $75.71.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.